Establish good sleep hygiene, and stick to a consistent wake-rest schedule
Studies show structured exercise and protein preserve 8590% of lean mass during GLP-1 therapy, so muscle loss is largely preventable through intentional choices rather than inevitable
The best results are achieved when the medication is part of a comprehensive, medically supervised weight loss program
AEs leading to trial product discontinuation occurred in 51/603 (8.5%) participants in the CagriSema 2.4 mg/2.4 mg group, 40/605 (6.6%) participants in the semaglutide 2.4 mg group, 7/152 (4.6%) participants in the cagrilintide 2.4 mg group, 42/594 (7.1%) participants in the CagriSema 1 mg/1 mg group, 26/608 (4.3%) participants in the semaglutide 1 mg group, and 2/149 (1.3%) participants in the placebo group
Key Takeaways Stanford researchers discovered a naturally occurring peptide called BRP that may support weight loss through appetite regulation In animal studies, BRP reduced food intake by nearly 50% within one hour and promoted fat loss without major side effects Unlike Ozempic and other GLP-1 drugs, BRP appears to work directly through the brains appetite centers rather than slowing digestion Researchers observed no significant nausea, digestive discomfort, or behavioral changes in animals treated with BRP With obesity rates continuing to rise globally, scientists are searching for safer and more tolerable medical weight loss options Behind the Discovery: What Is BRP
